Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;25(7):160-168.
doi: 10.1007/s11894-023-00874-9. Epub 2023 May 25.

Indications and safety of newer IBD treatments in the older patient

Benjamin Clement  1 , Kara De Felice  2 , Anita Afzali  1
Affiliations
Review

Indications and safety of newer IBD treatments in the older patient

Benjamin Clement et al. Curr Gastroenterol Rep. 2023 Jul.

Abstract

Purpose of review: Treatment of inflammatory bowel disease (IBD) in the elderly requires special attention to treatment efficacy while considering drug safety, other medical comorbidities, and the patients' risk for treatment related adverse events. In this article, we reviewed the indications and safety of the newer IBD therapies in the older IBD patient beyond anti-TNF agents, thiopurines, and corticosteroids.

Recent findings: Vedolizumab, ustekinumab, and risankizumab have favorable side effect profiles with regards to infections and malignancy. Ozanimod has a favorable side effect profile with regards to infection and malignancy, however cardiac events and macular edema are potential risks. Tofacitinib and upadacitinib are associated with an increased risk of serious infections, herpes zoster, malignancy, and have potential for an increased risk of cardiac events and thrombosis. From a safety profile perspective, vedolizumab, ustekinumab, and risankizumab should be considered first line treatment options for moderate-to-severe IBD in the elderly. Risk-benefit discussions are indicated for ozanimod, tofacitinib, and upadacitinib.

Keywords: Biologics; Efficacy; Elderly; Inflammatory Bowel Disease; Safety; Small molecules.

PubMed Disclaimer

References

    1. Sonnenberg A. Age distribution of IBD hospitalization. Inflamm Bowel Dis. 2010;16(3):452-7. - PubMed
    1. Zammarchi I, et al. Elderly-onset vs adult-onset ulcerative colitis: a different natural history? BMC Gastroenterol. 2020;20(1):147. doi: 10.1186/s12876-020-01296-x. - DOI - PMC - PubMed
    1. Jeuring SF, et al. Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity? Inflamm Bowel Dis. 2016;22(6):1425–1434. doi: 10.1097/MIB.0000000000000738. - DOI - PubMed
    1. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology, 2021;160(1):445-451. Evidence based clinical guidance for the treatment of elderly patients with IBD written by experts in the field. - PubMed
    1. White MC, et al. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7–15. doi: 10.1016/j.amepre.2013.10.029. - DOI - PMC - PubMed

MeSH terms